Crossmark

Efficacy and safety of low-molecular-weight heparin or rivaroxaban combined with immunotherapy and chemotherapy in the treatment of advanced nonsmall cell lung cancer: a prospective, randomized, controlled clinical study

Crossref DOI link: https://doi.org/10.1007/s00262-025-04227-5

Published Online: 2025-11-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhang, Hongchuan

Li, Junfeng

Yuan, Guangjin

Huang, Shengyuan

Li, Xuemei
Funding

Funding for this research was provided by:

the Chongqing Science and Health Joint Medical Research Project (2023MSXM072)

Dianjiang County Bureau of Science and Technology (djkjxm2022shmskjcxyw006)

Natural Science Foundation of Chongqing-Chongqing Science and Technology Development Foundation (CSTB2024NSCQ- KJFZMSX0035)
License Information

Text and Data Mining valid from 2025-11-12

Version of Record valid from 2025-11-12
More Information

Article History

Received: 4 July 2025

Accepted: 2 November 2025

First Online: 12 November 2025

Declarations

:

: The authors declare no competing interests.

: This study was approved by the Ethics Committee of Dianjiang County People’s Hospital in Chongqing (20220912).

: Informed consent was obtained from all individual participants included in the study.

Document is current

Any future updates will be listed below